How does diagnostic subtype affect the quality of primary care for people with dementia? A retrospective cohort study in 1490 English general practices
A recent retrospective cohort study utilizing the Clinical Practice Research Datalink (Aurum) database has revealed significant disparities in the provision of guideline-consistent primary care among different dementia subtypes. The analysis, which included 571,663 individuals from January 2006 to June 2024, assessed the likelihood of receiving care plans and medication reviews across eight dementia subtypes: Alzheimer’s disease (AD), Lewy body dementia (LBD), vascular dementia, frontotemporal dementia, unspecified, other, and two mixed categories. Notably, individuals with mixed dementias were found to be more likely to receive care plans compared to those with AD, with hazard ratios (HR) indicating a 29% and 37% increased likelihood for mixed AD/LBD and mixed non-AD/LBD, respectively.
The findings underscore a troubling trend: individuals diagnosed with non-AD dementias, including mixed subtypes, vascular, and LBD, were more likely to experience potentially inappropriate prescribing (PIP) across four critical indicators, including high anti-cholinergic burden drugs and benzodiazepines. Specifically, all non-AD dementia subtypes exhibited a higher likelihood of PIP compared to AD, suggesting that these patients may be at greater risk for suboptimal treatment and care outcomes. This inequity in primary care provision raises concerns about the adequacy of current clinical guidelines and the need for tailored approaches to manage diverse dementia presentations effectively.
The implications of this research are profound for the field of dementia care and pharmacotherapy. It highlights the urgent need for clinicians and researchers to address the disparities in care associated with dementia subtypes, particularly as new AD therapies emerge that could exacerbate existing inequities. This study advocates for enhanced awareness and targeted interventions to ensure equitable care across all dementia types, potentially reshaping clinical practice guidelines and informing future drug development strategies.
Source: academic.oup.com